All In Biotech

Drug Trial Radar · NCT03651765

Long Term Extension Trial of Setmelanotide

Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway

Last checked: Nov 20, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

205

Actual

Start

Jul 15, 2018

Primary completion

Jan 9, 2025

Study completion Jan 9, 2025

Sponsor

Lead sponsor
Rhythm Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the Melanocortin-4 (MC4) receptor in the leptin-melanocortin pathway.

Conditions

  • Obesity Associated With Defects in Leptin-melanocortin Pathway

Interventions

  • SetmelanotideDrug

    Once daily subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose up to 5.6 years

Locations

27 sites in 8 countries. Site status is shown where the registry gives one.

  • Synexus Clinical Research US, Inc. - Phoenix Southeast

    Chandler, Arizona

  • Honor Health Research Institute

    Scottsdale, Arizona

  • San Diego Wake Research

    San Diego, California

  • University of Florida College of Medicine

    Gainesville, Florida

  • Baystate Medical Center

    Springfield, Massachusetts

  • University at Buffalo

    Buffalo, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Research

    Raleigh, North Carolina

  • Obesity Institute, Geisinger Clinic

    Danville, Pennsylvania

  • Childrens Hospital of Philadephia

    Philadelphia, Pennsylvania

  • Synexus Clinical Research US, Inc.- Primary Care Associates, PC

    Anderson, South Carolina

  • Wake Research TN

    Chattanooga, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Seattle Children's Research Institute

    Seattle, Washington

  • Marshfield Clinic Research Institute

    Marshfield, Wisconsin

  • University of Alberta

    Edmonton, Alberta, Canada

  • Hôpital Trousseau

    Paris, France

  • Hôpital de la Pitié Salpêtrière

    Paris, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • University of Leipzig

    Leipzig, Germany

  • University of Ulm

    Ulm, Germany

  • University General Hospital of Patras

    Rio, Greece

  • Erasmus MC

    Rotterdam, Netherlands

  • Universidad Autónoma de Madrid

    Madrid, Spain

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • Wellcome Trust-MRC Institute of Metabolic Science

    Cambridge, United Kingdom

  • Hammersmith Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.